INSTITUTO-COORDENADAS
13.10.2020 12:46:08 CEST | Business Wire | Press release
Barcelona’s efforts to become a safe destination for tourists have meant that, of all of Europe’s main tourism destinations, the city and its surrounding areas have been ranked as one of most committed to health safety matters. Monitoring and advice, alongside the involvement of the tourism sector’s main actors, have provided Barcelona with international acknowledgment that will benefit the sector’s recovery. Those are the main conclusions of an ongoing study by Institute Coordenadas into the impact of Covid-19 on the tourism industry.
One of the key indicators that place Barcelona at the forefront for safe spaces internationally is the backing for the city from the World Travel and Tourism Council (WTTC), which has launched a global quality stamp for tourist destinations that provided the strongest guarantees that their public spaces are Covid-secure. Barcelona is a member of the elite group of major European cities that safely welcome a high number of tourists. As such, the city is striving to provide the safest conditions for visitors, around 28 million of whom come to the Catalan capital every year, joining its population of just over 1.6 million. Seville was also acknowledged by the WTTC, along with other destinations in Portugal, Saudi Arabia and Cancun, Mexico.
Barcelona’s seventh position (and the title of top-ranked Spanish city) in the Saffron City Brand Barometer 2020 of the cities with the strongest tourism brands is also a key factor. Similarly, the Global Safe Site certification from Bureau Veritas highlights strict compliance with hygiene and safety measures in Barcelona, which was also the first Spanish city to be awarded the distinction. Key tourist infrastructure such as Park Güell, the city’s zoo and the Tibidabo amusement park have all been awarded the Safe Tourism Certified distinction by the Institute for Spanish Tourism Quality (ICTE), which marks the implementation of a specific Covid-19 risk prevention system. Furthermore, Barcelona has been Biosphere-certified since 2011 as an urban destination committed to sustainability.
The website promoted by Barcelona City Council as part of the Barcelona Safe City/Safe Visit initiative is a key element in the process of getting the city moving again post-Covid. The portal can be used by companies and professionals to check the information related to their respective fields and for obtaining a personalised report featuring all the necessary elements to ensure protocols adapt to maximum safety requirements.
The involvement of actors from different municipal levels has been one of the factors that has allowed Barcelona to compete to become a safer city in terms of health. The Safe City initiative included an interdisciplinary working group with members from the Catalan Directorate of Tourism, the Public Health Agency of Catalonia, the Municipal Civil Defence Service, the Guàrdia Urbana municipal police force, BCNecologia/Barcelona Urban Ecology Agency, the city’s Department of Commerce, its Culture Institute and the Barcelona Sports Institute, municipal company B:SM, trade fair organisation Fira de Barcelona, the Turisme de Barcelona Consortium and ISGlobal.
Another aspect that will improve safety features for tourists in Barcelona is the introduction of the app currently being put together by the Turisme de Barcelona Consortium and Barcelona City Council. The app will allow users to check on health recommendations and the situation at visitor locations, so as to avoid crowds and queueing. The app’s initial launch phase will feature opening times and entry points for the most popular tourist destinations, along with guidance for health and mobility. Plans for the second phase include real-time information and the option of booking ahead to ensure safer management of tourist activities. The app is being developed by Eurecat Technology Centre in collaboration with the Mobile World Capital Barcelona Foundation and Barcelona Tech City.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005582/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
